Patents by Inventor Ali Roghanian

Ali Roghanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF
    Publication number: 20240092912
    Abstract: The present invention generally relates to antibody combinations and uses thereof.
    Type: Application
    Filed: March 9, 2022
    Publication date: March 21, 2024
    Inventors: Björn FRENDÉUS, Linda MÅRTENSSON, Ingrid TEIGE, Mark CRAGG, Robert OLDHAM, Stephen BEERS, Ali ROGHANIAN
  • COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES
    Publication number: 20230381310
    Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.
    Type: Application
    Filed: March 1, 2023
    Publication date: November 30, 2023
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige
  • Combined use of Fc?RIIb (CD32B) and CD20 specific antibodies
    Patent number: 11623005
    Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: April 11, 2023
    Assignee: UNIVERSITY OF SOUTHAMPTON
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige
  • COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES
    Publication number: 20210346498
    Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 11, 2021
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Björn Frendéus, Ingrid Teige
  • NOVEL COMBINATION AND USE OF ANTIBODIES
    Publication number: 20200362036
    Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 19, 2020
    Inventors: Björn Frendéus, Ingrid Teige, Linda Mårtensson, Mark Cragg, Stephen Beers, Ali Roghanian, Robert Oldham
  • COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES
    Publication number: 20200069798
    Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 5, 2020
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige
  • Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies
    Patent number: 10525129
    Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: January 7, 2020
    Assignee: University of Southampton
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige
  • MEDICAMENTS, USES AND METHODS
    Publication number: 20170107293
    Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 20, 2017
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Björn Frendéus, Ingrid Teige, Linda Mårtensson, Mark Cragg, Ali Roghanian
  • COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 - SPECIFIC ANTIBODIES
    Publication number: 20130251706
    Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.
    Type: Application
    Filed: August 19, 2011
    Publication date: September 26, 2013
    Applicant: UNIVERSITY OF SOUTHAMPTON
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige